379 related articles for article (PubMed ID: 9950100)
1. The use of BRM-activated killer cells in adoptive immunotherapy: a pilot study with nine advanced cancer patients.
Ebina T; Fujimiya Y; Yamaguchi T; Ogama N; Sasaki H; Isono N; Suzuki Y; Katakura R; Tanaka K; Nagata K; Takano S; Tamura K; Uno K; Kishida T
Biotherapy; 1998; 11(4):241-53. PubMed ID: 9950100
[TBL] [Abstract][Full Text] [Related]
2. Effector mechanism and clinical response of BAK (BRM-activated killer) immuno-cell therapy for maintaining satisfactory QOL of advanced cancer patients utilizing CD56-positive NIE (neuro-immune-endocrine) cells.
Ebina T; Ogama N; Shimanuki H; Kubota T; Isono N
Microbiol Immunol; 2001; 45(5):403-11. PubMed ID: 11471830
[TBL] [Abstract][Full Text] [Related]
3. Life-prolonging effect of immunocell BAK (BRM-activated killer) therapy for advanced solid cancer patients: prognostic significance of serum immunosuppressive acidic protein levels.
Ebina T; Ogama N; Shimanuki H; Kubota T; Isono N
Cancer Immunol Immunother; 2003 Sep; 52(9):555-60. PubMed ID: 14627127
[TBL] [Abstract][Full Text] [Related]
4. [Regional adoptive immunotherapy using activated lymphocytes].
Ebina T; Isono N; Murata K; Yokoyama J; Mikuni J; Ohuchi K
Gan To Kagaku Ryoho; 1996 Sep; 23(11):1549-52. PubMed ID: 8854802
[TBL] [Abstract][Full Text] [Related]
5. Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer.
Sun Z; Shi L; Zhang H; Shao Y; Wang Y; Lin Y; Li X; Bai C
Clin Immunol; 2011 Jan; 138(1):23-32. PubMed ID: 21041120
[TBL] [Abstract][Full Text] [Related]
6. [Life-prolonging effect of immunocell BAK (BRM activated killer) therapy--evidence based integrative medicine].
Ebina T
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1643-5. PubMed ID: 15553670
[TBL] [Abstract][Full Text] [Related]
7. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M
Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906
[TBL] [Abstract][Full Text] [Related]
8. [Local injection of BRM-activated killer cells into an abdominal wall tumor].
Ebina T
Gan To Kagaku Ryoho; 2013 Nov; 40(11):1507-9. PubMed ID: 24231704
[TBL] [Abstract][Full Text] [Related]
9. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.
Fujimiya Y; Suzuki Y; Katakura R; Miyagi T; Yamaguchi T; Yoshimoto T; Ebina T
Clin Cancer Res; 1997 Apr; 3(4):633-43. PubMed ID: 9815731
[TBL] [Abstract][Full Text] [Related]
10. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
11. Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors.
Noguchi A; Kaneko T; Kamigaki T; Fujimoto K; Ozawa M; Saito M; Ariyoshi N; Goto S
Cytotherapy; 2011 Jan; 13(1):92-7. PubMed ID: 20831354
[TBL] [Abstract][Full Text] [Related]
12. Change in peripheral blood lymphocyte count in dogs following adoptive immunotherapy using lymphokine-activated T killer cells combined with palliative tumor resection.
Mie K; Shimada T; Akiyoshi H; Hayashi A; Ohashi F
Vet Immunol Immunopathol; 2016 Sep; 177():58-63. PubMed ID: 27436446
[TBL] [Abstract][Full Text] [Related]
13. Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC.
Hayakawa K; Salmeron MA; Parkinson DR; Markowitz AB; von Eschenbach AC; Legha SS; Balch CM; Ross MI; Augustus LB; Itoh K
J Immunother (1991); 1991 Oct; 10(5):313-25. PubMed ID: 1790139
[TBL] [Abstract][Full Text] [Related]
14. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
[TBL] [Abstract][Full Text] [Related]
15. Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-alpha beta+, TCR-gamma delta+ T lymphocytes, and NK cells.
Perussia B; Chan SH; D'Andrea A; Tsuji K; Santoli D; Pospisil M; Young D; Wolf SF; Trinchieri G
J Immunol; 1992 Dec; 149(11):3495-502. PubMed ID: 1358972
[TBL] [Abstract][Full Text] [Related]
16. [Non-small cell lung cancer--immunocell BAK (BRM activated killer) therapy].
Ebina T
Nihon Rinsho; 2006 Jul; 64(7):1339-44. PubMed ID: 16838654
[TBL] [Abstract][Full Text] [Related]
17. Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.
Gratama JW; Bruin RJ; Lamers CH; Oosterom R; Braakman E; Stoter G; Bolhuis RL
Clin Exp Immunol; 1993 May; 92(2):185-93. PubMed ID: 8485906
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo-expanded natural killer cells kill cancer cells more effectively than ex vivo-expanded γδ T cells or αβ T cells.
Deng X; Terunuma H; Terunuma A; Takane T; Nieda M
Int Immunopharmacol; 2014 Oct; 22(2):486-91. PubMed ID: 25131561
[TBL] [Abstract][Full Text] [Related]
19. gammadelta-T cells expressing NK receptors predominate over NK cells and conventional T cells in the innate IFN-gamma response to Plasmodium falciparum malaria.
D'Ombrain MC; Hansen DS; Simpson KM; Schofield L
Eur J Immunol; 2007 Jul; 37(7):1864-73. PubMed ID: 17557374
[TBL] [Abstract][Full Text] [Related]
20. The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity.
Watanabe H; Narumi K; Stewart CC; Arbuck SG; Foon KA; Goldrosen MH
Anticancer Res; 1992; 12(6B):1925-33. PubMed ID: 1295440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
